RxDoctor Payments Data

Jerry Watson, MD

Interventional Cardiology · Myrtle Beach, SCNPI 1174519896

Payments from drug & device makers

$2,065in general payments, 2019–2025

Across 89 payments — averaging $23.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$392
  • Novartis$305
  • Amgen$188
  • Pfizer$187
  • Cvrx, Inc.$164
  • E.r. Squibb & Sons, L.L.C.$142
  • plus $687 from 10 others

What the payments were for

  • Food & beverage$2,05199%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,065 in reported general payments places this provider in the 10th percentile of 117 interventional cardiology providers in South Carolina.

See all interventional cardiology providers in South Carolina

Medicare billing

Part B allowed, 2024
$341,365
Medicare patients
1,241
Services billed
3,617

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban487$591,677
EntrestoSacubitril/Valsartan104$146,148
Repatha SureclickEvolocumab114$121,541
XareltoRivaroxaban64$85,227
FarxigaDapagliflozin Propanediol47$30,354
Rosuvastatin Calcium287$6,322
Metoprolol Succinate382$6,040
Prasugrel Hcl48$3,746
ClopidogrelClopidogrel Bisulfate243$3,075
Atorvastatin Calcium286$2,754
Metoprolol Tartrate321$2,570
Losartan Potassium286$2,547
Carvedilol240$2,213
Hydralazine Hcl119$1,959
Lisinopril230$1,717

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$187$591,677487 claims
NovartisEntresto$305$146,148104 claims
AstraZenecaFarxiga$78$30,35447 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 117 interventional cardiology providers in South Carolina.

Other interventional cardiology in Myrtle Beach

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →